MedTrace Logo

Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial

NCT01908465 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2023-02-08

No results posted yet for this study

Summary

Purpose:

To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the H1-receptor antagonist ebastine.

Design:

Double blind randomized placebo controlled trial. IBS patients receive a 12-weeks treatment with ebastine 20mg once daily or placebo (1:1 randomization).

Conditions

  • Irritable Bowel Syndrome (IBS)

Interventions

DRUG

Ebastine

DRUG

Placebo

Sponsors & Collaborators

  • KU Leuven

    lead OTHER

Principal Investigators

  • Guy Boeckxstaens, M.D. · Catholic University Leuven and Universitary Hospitals Leuven

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2022-11-02
Completion
2022-11-02

Countries

  • Belgium
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01908465 on ClinicalTrials.gov